A citation-based method for searching scientific literature

Parasvi S Patel, Arash Algouneh, Razq Hakem. Oncogene 2021
Times Cited: 10







List of co-cited articles
62 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.
Pedro A Mateos-Gomez, Fade Gong, Nidhi Nair, Kyle M Miller, Eros Lazzerini-Denchi, Agnel Sfeir. Nature 2015
341
40

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
40

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
30

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
30

Essential Roles for Polymerase θ-Mediated End Joining in the Repair of Chromosome Breaks.
David W Wyatt, Wanjuan Feng, Michael P Conlin, Matthew J Yousefzadeh, Steven A Roberts, Piotr Mieczkowski, Richard D Wood, Gaorav P Gupta, Dale A Ramsden. Mol Cell 2016
118
30

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
30

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
30

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
30

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Raphael Ceccaldi, Jessica C Liu, Ravindra Amunugama, Ildiko Hajdu, Benjamin Primack, Mark I R Petalcorin, Kevin W O'Connor, Panagiotis A Konstantinopoulos, Stephen J Elledge, Simon J Boulton,[...]. Nature 2015
394
30

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
30

The essential kinase ATR: ensuring faithful duplication of a challenging genome.
Joshua C Saldivar, David Cortez, Karlene A Cimprich. Nat Rev Mol Cell Biol 2017
302
20

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
627
20

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Guotai Xu, J Ross Chapman, Inger Brandsma, Jingsong Yuan, Martin Mistrik, Peter Bouwman, Jirina Bartkova, Ewa Gogola, Daniël Warmerdam, Marco Barazas,[...]. Nature 2015
328
20

Genomic instability--an evolving hallmark of cancer.
Simona Negrini, Vassilis G Gorgoulis, Thanos D Halazonetis. Nat Rev Mol Cell Biol 2010
20

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
328
20

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Seng-Ryong Woo, Mercedes B Fuertes, Leticia Corrales, Stefani Spranger, Michael J Furdyna, Michael Y K Leung, Ryan Duggan, Ying Wang, Glen N Barber, Katherine A Fitzgerald,[...]. Immunity 2014
746
20

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
377
20

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
Vassilis G Gorgoulis, Leandros-Vassilios F Vassiliou, Panagiotis Karakaidos, Panayotis Zacharatos, Athanassios Kotsinas, Triantafillos Liloglou, Monica Venere, Richard A Ditullio, Nikolaos G Kastrinakis, Brynn Levy,[...]. Nature 2005
20

Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Kristen E Mengwasser, Richard O Adeyemi, Yumei Leng, Mei Yuk Choi, Connor Clairmont, Alan D D'Andrea, Stephen J Elledge. Mol Cell 2019
70
20

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
20

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.
Jirina Bartkova, Zuzana Horejsí, Karen Koed, Alwin Krämer, Frederic Tort, Karsten Zieger, Per Guldberg, Maxwell Sehested, Jahn M Nesland, Claudia Lukas,[...]. Nature 2005
20

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
J K Litton, S A Hurvitz, L A Mina, H S Rugo, K-H Lee, A Gonçalves, S Diab, N Woodward, A Goodwin, R Yerushalmi,[...]. Ann Oncol 2020
44
20

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020
57
20

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Heidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, Mihaela Cristea, Hao Xiong, Danielle Sullivan, Yan Luo, Mark D McKee, Wijith Munasinghe, Lainie P Martin. Gynecol Oncol 2018
40
20

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Sergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, Bo Zhao, Nail Fatkhutdinov, Andrew V Kossenkov, Andrew J Wilson, Fiona Simpkins, David Speicher, Dineo Khabele,[...]. Cell Rep 2017
72
20

The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Samuel C Fehling, Aubrey L Miller, Patrick L Garcia, Rebecca B Vance, Karina J Yoon. Cancer Lett 2020
8
25

PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Sylvie M Noordermeer, Haico van Attikum. Trends Cell Biol 2019
113
20

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
42
20

Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Ross A Stewart, Patrick G Pilié, Timothy A Yap. Cancer Res 2018
86
20

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
699
20

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
752
20

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
193
20

DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability.
Fanny Lemée, Valérie Bergoglio, Anne Fernandez-Vidal, Alice Machado-Silva, Marie-Jeanne Pillaire, Anne Bieth, Catherine Gentil, Lee Baker, Anne-Laure Martin, Claire Leduc,[...]. Proc Natl Acad Sci U S A 2010
106
20

DNA polymerase theta suppresses mitotic crossing over.
Juan Carvajal-Garcia, K Nicole Crown, Dale A Ramsden, Jeff Sekelsky. PLoS Genet 2021
6
33

Mechanism of suppression of chromosomal instability by DNA polymerase POLQ.
Matthew J Yousefzadeh, David W Wyatt, Kei-Ichi Takata, Yunxiang Mu, Sean C Hensley, Junya Tomida, Göran O Bylund, Sylvie Doublié, Erik Johansson, Dale A Ramsden,[...]. PLoS Genet 2014
144
20

Human DNA polymerase θ grasps the primer terminus to mediate DNA repair.
Karl E Zahn, April M Averill, Pierre Aller, Richard D Wood, Sylvie Doublié. Nat Struct Mol Biol 2015
73
20

DNA polymerase θ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
Zi Wang, Yadong Song, Shibo Li, Sunil Kurian, Rong Xiang, Takuya Chiba, Xiaohua Wu. J Biol Chem 2019
39
20

Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
Anna Schrempf, Jana Slyskova, Joanna I Loizou. Trends Cancer 2021
17
20

POLQ (Pol theta), a DNA polymerase and DNA-dependent ATPase in human cells.
Mineaki Seki, Federica Marini, Richard D Wood. Nucleic Acids Res 2003
128
20


Genetic determinants of cellular addiction to DNA polymerase theta.
Wanjuan Feng, Dennis A Simpson, Juan Carvajal-Garcia, Brandon A Price, Rashmi J Kumar, Lisle E Mose, Richard D Wood, Naim Rashid, Jeremy E Purvis, Joel S Parker,[...]. Nat Commun 2019
47
20

A Polymerase Theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites.
Wouter Koole, Robin van Schendel, Andrea E Karambelas, Jane T van Heteren, Kristy L Okihara, Marcel Tijsterman. Nat Commun 2014
130
20

Low-fidelity DNA synthesis by human DNA polymerase theta.
Mercedes E Arana, Mineaki Seki, Richard D Wood, Igor B Rogozin, Thomas A Kunkel. Nucleic Acids Res 2008
95
20


Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.
Stephen J Pettitt, Jessica R Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A Yap, Syed Haider, Andrew N J Tutt, Christopher J Lord. Cancer Discov 2020
30
20

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
360
20

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
405
20

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
644
20

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
658
20

A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors.
Xiaoteng Cui, Xinxin Zhang, Minghui Liu, Chunyan Zhao, Nan Zhang, Yuanyuan Ren, Chao Su, Wei Zhang, Xiaoming Sun, Jinyan He,[...]. Genomics 2020
17
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.